Morepen Laboratories Secures ₹30 Crore Loan from Shinhan Bank for Business Needs

Morepen Laboratories Limited has entered into a loan agreement with Shinhan Bank to avail an unsecured term loan facility worth ₹30 crore. The agreement was approved by the Finance Committee of the company’s Board of Directors during its meeting held on April 23, 2026.

The loan has been taken to support general business operations, reflecting the company’s strategy to strengthen its financial position and operational capabilities.

Key Terms of the Loan Agreement

The credit facility is structured as a term loan of ₹30 crore with an interest rate of 7.60%, calculated as the repo rate of 5.25% plus a spread of 2.35%.

The tenure of the loan is set at 36 months. Repayment will be made through 10 equal quarterly instalments, following a moratorium period of six months. This structure provides initial flexibility before repayment obligations begin.

Guarantee and Security Details

The loan is supported by a personal guarantee from Sushil Suri, who serves as the promoter, chairman, and managing director of the company. No equity or shareholding has been provided to the lender as part of the agreement.

There are no additional special rights granted to the lender, such as board representation or control over capital structure, making this a straightforward financing arrangement.

Existing Debt Position

Before this loan, Morepen Laboratories had a total outstanding loan exposure of ₹182.62 crore, excluding vehicle loans and interest. Out of this, ₹20.45 crore was already outstanding with Shinhan Bank.

The addition of this facility indicates continued reliance on structured financing to support business growth and working capital requirements.

Morepen Laboratories Share Price Today

On April 24, 2026, Morepen Laboratories share price opened at ₹42.81, touching the day’s low at ₹41.83, as of 10:13 AM on the NSE.

Also Read: Morepen Laboratories Secures ₹825 Crore Multi-Year CDMO Mandate from Global Pharma Major!

Conclusion

The ₹30 crore term loan agreement highlights Morepen Laboratories’ focus on maintaining liquidity and supporting its operational needs. With a defined repayment structure and promoter-backed guarantee, the company appears to be balancing growth ambitions with financial discipline. Investors may view this development as part of the company’s broader strategy to strengthen its balance sheet and fund ongoing business activities.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.